ZIOPHARM Oncology Inc (ZIOP) was among the biggest gainers on the Russell 2000 for Wednesday January 20 as the stock popped 5.85% to $5.79, representing a gain of $0.32 per share. Some 2.86 million shares traded hands on 11,561 trades, compared with an average daily volume of 3.1 million shares out of a total float of 130.89 million. The stock opened at $5.25 and traded with an intraday range of $5.90 to $4.90.
After today's gains, ZIOPHARM Oncology Inc reached a market cap of $757.85 million. ZIOPHARM Oncology Inc has had a trading range between $14.93 and $4.66 over the last year, and it had a 50-day SMA of $10.06 and a 200-day SMA of $10.57.
ZIOPHARM Oncology Inc is a biopharmaceutical company. The Company is engaged in the acquiring, developing and commercializing portfolio of cancer therapies that can address unmet medical needs through synthetic biology.
ZIOPHARM Oncology Inc is based out of Boston, MA and has some 27 employees. Its CEO is Laurence James Neil Cooper.
For a complete fundamental analysis analysis of ZIOPHARM Oncology Inc, check out Equities.com’s Stock Valuation Analysis report for ZIOP. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.